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ABSTRACT 
 The most well studied cancer-related gene in history, p53, is responsible for 
protecting the integrity of the genome.  A variety of different stresses are detected by p53 
and its regulators, allowing for numerous post-translational modifications that activate 
p53.  After activation p53 can then regulate transcription of a myriad downstream targets, 
resulting in either cell cycle arrest or apoptosis.  One of the stress signals that activates 
p53 is viral infection in part through the induction of type-1 interferon.  However some 
viruses, like the DNA tumor viruses have evolved factors capable of binding to p53 and 
inhibiting its ability to regulate its downstream factors in order to avoid cell cycle arrest 
or apoptosis and complete the viral life cycle.  The human immunodeficiency virus 
(HIV), probably the most notorious virus of our time because of our inability to 
completely eradicate it from a host, is capable of activating p53 in certain cell types upon 
infection.  Several studies have reported on the functions of p53 during HIV infection, 
such as inhibiting full-length transcription of HIV, interaction with a number of HIV-
encoded proteins such as the trans-activator of transcription (Tat), and eventual wide-
spread apoptosis in T-cells, however these disparate roles are undoubtedly not the whole 
story.  Our hypothesis is that an HIV factor, Tat is capable of mitigating the downstream 
effects of p53.  To test this hypothesis we used U2-OS cells and created U2-OS cell lines 
that express Tat protein.  These cells were then treated with the DNA damaging agents to 
activate p53.  At various time post treatment, we measured promoter activity, mRNA and 
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protein expression of p53 and its targets p21 and bax.  Without further investigation, at 
the present time we have no convincing evidence that Tat inhibits p53 function.   
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CHAPTER 1 
INTRODUCTION 
1.1 CELLULAR ROLE OF p53  
p53, a protein now famous for its function as a tumor suppressor, was discovered 
because of its binding with Simian vacuolating virus 40 (SV40) large tumor (T) antigen, 
a viral protein essential for initiation and maintenance of cellular transformation (Lane 
and Crawford 1979).  First suspected of being an oncogene because of the ability of some 
p53 cDNA to transform normal cells to tumorigenic cells (Eliyahu, Raz et al. 1984; 
Parada, Land et al. 1984), these cDNA were eventually recognized as mutant forms, 
while wild-type p53 could prevent transformation (Finlay, Hinds et al. 1989).  Several 
discoveries demonstrated the importance of p53 for tumor suppression.  Mutations in p53 
have been found in almost every type of cancer and at rates of up to 50% (Olivier, 
Hollstein et al. 2010),  p53-/- mice were found to develop normally but acquire tumors 
very early (Donehower, Harvey et al. 1992) and mutant p53 was found at high levels in a 
wide range of human cancers (Bartek, Bartkova et al. 1991).  Determining the role of 
wild-type p53 in maintaining genetic stability was becoming increasingly significant and 
when it was finally uncovered, p53 was dubbed the “guardian of the genome” (Lane 
1992).   
The most notable function of wild-type p53 is that of transcription factor.  The 
p53 protein recognizes and binds to regions of DNA called response elements (REs) 
found in certain promoters (El-Deiry, Kern et al. 1992) and increases transcription of the 
 2 
 
corresponding genes (Farmer, Bargonetti et al. 1992).  The set of genes regulated will 
ultimately determine the fate of the cell.  One possible cellular outcome is programmed 
cell death or apoptosis (Shaw, Bovey et al. 1992) and can be achieved through inducing a 
number of genes such as Bax, PUMA, Noxa, and Fas (Benchimol 2001) that are involved 
in permeablization of the mitochondrial membrane and the caspase cascade.  In other 
circumstances a more appropriate state for the cell might be cell cycle arrest, either 
temporary or permanent arrest known as senescence.  In these situations p53 moderates 
genes involved in cell cycle progression such as p21, a cyclin dependent kinase (CDK) 
inhibitor, or cdc25c that mediates initiation of mitosis, to stop advancement of the cell 
cycle (El-Deiry, Tokino et al. 1993; Clair, Giono et al. 2004) (Figure 1.1).  
The need for such disparate consequences stems from the ability of p53 to 
respond to numerous forms of cellular stress including, but not limited to, viral infection, 
Figure 1.1 The p53 pathway.  A diverse assortment of stress signals can be recognized 
by the p53 core regulatory molecules through post-translational modifications.  
Activation of p53 then leads to three possible responses, apoptosis, cell cycle arrest 
and senescence.  (From Levine 2009). 
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oncogenes, and genotoxic agents (Levine 1997).  These stresses lead to a number of 
posttranslational modifications (PTMs) of the p53 protein that can cause its stabilization, 
localization to the nucleus, increased binding to the REs of its target genes, and moderate 
interactions with its binding partners (Gu and Zhu 2012).  The types of PTM that the p53 
protein can undergo include phosphorylation, methylation, glycosylation, and 
ubiquitylation to name a few (Meek and Anderson 2009).   Specifically there are at least 
a handful of residues subject to acetylation on the p53 protein by more than one enzyme.  
Lysine 120 is acetylated by Tip60, a histone acetyltransferase, after DNA damage and 
while this alteration is necessary for induction of apoptosis it is not required for cell cycle 
arrest (Tang, Luo et al. 2006).  While certain PTMs appear to work in an individual 
“switch-like” fashion, there is also evidence for cooperative and sequential effects (Gu 
and Zhu 2012).  The type and intensity of the cellular stimuli induce different PTM 
patterns which function to fine-tune the p53 response for a particular outcome.   
Activation of p53 by cellular stress is achieved in part by manipulating its 
interactions with its negative regulators, primarily murine double minute 2 (mdm2).  
Under normal cellular conditions p53 activity is kept in check by a number of negative 
regulators through strict control of protein levels and spatial separation from its targets.  
This is partially accomplished by complex formation with the mdm2 protein (Momand, 
Zambetti et al. 1992) which blocks the p53 transactivation domain (Lin, Chen et al. 1994) 
and acts as a ubiquitin ligase targeting p53 for degradation (Haupt, Maya et al. 1997; 
Kubbutat, Jones et al. 1997).  Nuclear export of p53 through exposure of the nuclear 
export sequence (NES) or the NES of mdm2 in the mdm2 p53 complex (Roth, 
Dobbelstein et al. 1998; Stommel, Marchenko et al. 1999) helps regulate p53 activity by 
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physically separating p53 protein from its target binding sites.  Mdm4, a protein similar 
to mdm2, is also necessary for regulation of p53, but in a manner nonoverlapping with 
that of mdm2 (Parant, Chavez-Reyes et al. 2001).  Mdm2 and mdm4 are so imperative 
for controlling the activity of p53 that mouse embryos deficient in either do not survive to 
birth unless also deficient for p53 (de Oca Luna, Wagner et al. 1995; Jones, Roe et al. 
1995; Migliorini, Denchi et al. 2002). 
However when cells become stressed from DNA damage or other trauma the 
negative regulators of p53 are inhibited.  For example during the DNA damage response 
to ionizing radiation mdm2 is inhibited from binding to p53 because of phosphorylation 
of p53 by ataxia telangiectasia mutated (ATM) (Kastan 2008).  ATM simultaneously 
phosphorylates mdm2 and mdm4 hastening their rapid degradation (Chen, Gilkes et al. 
2005; Stommel and Wahl 2005).  This leads to a physical release of p53 protein from 
mdm2 and an accumulation of p53 protein and downstream activity.  An alternate 
pathway to p53 activation through its negative regulator mdm2 is caused by oncogene 
activation.  Stimulation of several oncogenes, including Ras and Myc, lead to an increase 
in arf protein (Palmero, Pantoja et al. 1998; Zindy, Eischen et al. 1998). Arf protein then 
binds mdm2 inhibiting its regulation of p53 and contributes to p53 accumulation and 
stimulation of its cellular effects (Pomerantz, Schreiber-Agus et al. 1998; Zhang, Xiong 
et al. 1998).  Clearly inhibition and destabilization help uncouple p53 from its negative 
regulators through direct binding and PTM and contribute to the p53 stress response. 
p53 is one of the most well studied regulators of genomic stability, especially in 
its role as a tumor suppressor.  Even though it was first detected in complex with a viral 
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protein, the role of p53 in viral infections has not been as well characterized, particularly 
in relation to the most infamous virus of our time, HIV.   
 
1.2 VIRAL INFECTION AND p53 
After its initial discovery in SV40 infected cells, the p53 protein was shown to 
bind to the human  Papilloma virus-16 and 18 E6 (Werness, Levine et al. 1990), and the 
Adenovirus E1b-55Kd protein (Sarnow, Ho et al. 1982), both viral proteins necessary for 
host cell transformation (Figure 1.2).  Eventually the purpose of the interaction between 
the viral proteins and p53 became evident, to inactivate p53 and protect the infected cell 
from p53-induced cell cycle arrest and apoptosis (Levine 2009), mimicking the role of 
the cellular factor mdm2.  The number of viral factors found to mitigate the activity of 
p53 either by direct interaction or by upstream or downstream effects is already 
substantial and continuing to grow (Sato and Tsurumi 2012).  However the role of p53 in 
the innate antiviral response is still not completely elucidated.  Interferons (IFNs) and 
other pro-inflammatory cytokines are central to the host response to viral infection.  An 
intriguing topic of research considers the factors elicited during the IFN response and 
their interactions with p53.   
Figure 1.2 Binding of p53 by proteins from the DNA 
tumor viruses including the large T antigen, E1B 
protein, and E6 protein.  (Adapted from Werness, 
Levine et al 1990) 
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The induction method of type 1 IFNs is dependent on the type of infecting virus 
and on cell type, and it involves multiple pathways for sensing infection (Perry, Chen et 
al. 2005).  A cellular response to infection is triggered by conserved molecular motifs 
called pathogen-associated molecular patterns (PAMPs) that can be found on viral 
nucleic acids packaged in endosomes, cytoplasmic viral nucleic acids, and viral proteins 
(Randall and Goodbourn 2008).  These triggers can be sensed through two distinct 
pathways, the extracytoplasmic and cytoplasmic both utilizing pattern recognition 
receptors (PRRs).  The extracytoplasmic pathway consists of the family of Toll-like 
receptors (TLRs), membrane bound proteins that recognize PAMPs in the environment 
and recruit the corresponding signaling components and transcription factors using their 
cytoplasmic domains (Garcia-Sastre and Biron 2006).  Certain host cell proteins in the 
cytoplasm, like the RNA helicases RIG-1 and mda5, have also been classified as PRRs 
since they have been demonstrated to recognize viral nucleic acids and stimulate 
production of IFNs (Garcia-Sastre and Biron 2006).   
While differing combinations of PAMP and PRR may be responsible for 
activating unique pathways to IFN transcription, there seem to be a handful of common 
factors.  Nuclear factor kappa-B (NF-κB) and members of the IFN regulatory factor (IRF) 
family must be translocated to the nucleus from the cytoplasm for transcription of the 
type 1 IFNs to occur (Randall and Goodbourn 2008).  Type 1 IFNs are released from the 
cell where they can enhance the innate antiviral response, in both an autocrine and 
paracrine manner, by binding to type 1 IFN receptors (Perry, Chen et al. 2005).   
Type 1 IFN receptors are transmembrane proteins consisting of two subunits IFN 
α/β receptor 1 (IFNAR1) and IFN α/β receptor 2 (IFNAR2) which dimerize upon IFN 
 7 
 
type 1 binding (Stark, Kerr et al. 1998).  This interaction activates two members of the 
the Janus family of tyrosine kinases, JAK-1 a nd TYK-2 which phosphorylate the 
signaling transducer and activator of transcription (STAT) 1 and 2 (Platanias and Fish 
1999).  The activated forms of STAT1 and 2 then complex with IRF9 to form IFN-
stimulated gene factor 3 (ISGF3) that is transported to the nucleus and binds to DNA 
sequences containing IFN-stimulated response elements (ISREs) to upregulate 
transcription of IFN-stimulated genes (ISGs).  Other IFN-activated STATs and STAT 
complexes are also reported to be capable of DNA binding and transcription activation 
(Garcia-Sastre and Biron 2006).    
The p53 promoter contains sequences similar to ISREs capable of being bound by 
ISGF3.  This helps explain the induction of p53 mRNA and protein upon treatment with 
IFN-α/β (Takaoka, Hayakawa et al. 2003).  When this induction occurs early, less than 9 
hours post treatment, it does not in itself result in activation of p53 or regulation of the 
downstream targets of p53.  On the other hand prolonged exposure to IFN-β, 3-12 days, 
can lead to permanent cell cycle arrest at least partially due to PTM and activation of p53 
(Moiseeva, Mallette et al. 2006).   
However infection of MEFs with vesicular stomatitis virus (VSV) induces IFN-β, 
p53 with and without PTMs, and some downstream targets of p53 within 16 hours.  At 24 
hours post infection p53-/- MEFs show an increased resistance to apoptosis when 
compared to MEFs wild-type for p53.  Also the viral yield in VSV infected MEFs was 
30-fold greater when p53 was not present (Takaoka, Hayakawa et al. 2003).  In fact 
“super p53” MEFs, generated from mice receiving an extra copy of p53, demonstrated 
even less tolerance for VSV replication as measured by viral yield, and showed increased 
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levels of PUMA and apoptotic cells (Munoz-Fontela, Angel Garcia et al. 2005).  
Infection with influenza virus also upregulates p53 protein and activity, cell type 
independently.  There was a severe decrease in the viability of influenza virus infected 
cells when p53 was present and functional, and an increase in viral yield when p53 is 
inhibited (Turpin, Luke et al. 2005). 
The actions of p53 may also be regulated by factors in the antiviral IFN response 
pathway other than IFN itself.  Protein kinase R (PKR) is a type 1 IFN inducible target 
that binds and is activated by dsRNA from viral infections as well as cellular activators 
such as PACT (Patel and Sen 1998).  PKR halts viral replication through phosphorylation 
of the cellular translation initiation faction eIF2 inhibiting viral protein synthesis 
(Colthurst, Campbell et al. 1987).  PKR has also been reported to increase IFN 
production probably through the activation of NF-κB (Perry, Chen et al. 2005).  The 
interactions of PKR with p53 have been implicated in the antiviral host response.  PKR 
has been reported to bind and phosphorylate the p53 protein at Ser392, and enhance 
phosphorylation of Ser18 increasing its transcription activity (Cuddihy, Li et al. 1999; 
Cuddihy, Wong et al. 1999).  Another method for p53 upregulation by proteins involved 
in the IFN pathway concerns the ability of STAT1 to negatively regulate Mdm2 and 
physically interact with p53 in response to DNA damage leading to induction of certain 
pro-apoptotic p53 gene targets (Townsend, Scarabelli et al. 2004). 
 This evidence supports the idea that p53 plays a role in virus-induced senescence 
and apoptosis, and modulation of viral replication. Lastly there is evidence for p53 
directly targeting several members of the type 1 IFN response for upregulation, including 
IRF9, TLR3, IRF5, and ISG15 (Rivas, Aaronson et al. 2010), increasing activity of the 
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IFN promoter ISRE (Turpin, Luke et al. 2005), and enhancing cellular release of IFN 
(Munoz-Fontela, Macip et al. 2008).  This would seem to indicate the presence of a 
positive feedback loop involving p53 and the IFN-mediated antiviral response pathway 
(Figure 1.3).  Therefore viral infections triggering an IFN response could also provoke 
p53 activation leading to cell cycle arrest, or apoptosis.  Depending on the life cycle of 
the virus it might prove advantageous to evolve factors to mitigate the p53 response. 
  
1.3 HUMAN IMMUNODEFIENCY VIRUS TYPE 1 
 Acquired immune deficiency syndrome (AIDS) is characterized by a set of 
symptoms, including recurrent infections, certain cancers, and low CD4+ T cell counts, 
and develops as infection by human immunodeficiency virus (HIV) before progressing to 
Figure 1.3 Feedback loop involving p53 and type 1 interferon. Viral infection 
leads to induction of type 1 IFN and p53 which results in induction of pro-
apoptotic genes and genes involved in the innate immune response.  (Rivas, 
Aaronson et al. 2010)   
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the final stage.  The Centers for Disease Control and Prevention (CDC) estimates that 39 
million people worldwide have died from AIDS since the epidemic began and another 35 
million people are living with the virus as of 2013.  Of those 35 million infected, only 
12.9 million were believed to be receiving antiretroviral therapy (ART).  Most 
antiretroviral drugs target the enzymes necessary for HIV infection and/or replication to 
occur.  ART is highly effective especially when used in combination regimens.  When 
three of more antiretroviral drugs are taken together it is called highly active 
antiretroviral therapy (HAART).  Although HAART can efficiently minimize viral load, 
specific characteristics of HIV make it necessary to continue therapy indefinitely to 
maintain this effect.   The complexity of the interactions between HIV and the innate 
immune system along with the propensity of HIV to rapid mutation have led to a 
challenging scientific and medical issue.  
HIV is of the family Retroviridae because it contains RNA and reverse 
transcriptase and was further classified as a lentivirus due to its similarity in sequence and 
morphology to known members of the Lentivirinae genus (Gonda, Wong-Staal et al. 
1985).  Based on its genetic diversity, HIV was further divided into HIV-1 and HIV-2.  
HIV-2 however displays much lower transmission efficiency and is therefore mostly 
restricted to West Africa and is endemic as opposed to the pandemic spread seen by HIV-
1 (Reeves and Doms 2002).   
 HIV-1 infection can be described in two stages; early and late.  The early stage 
describes the process of the mature virus entering the cell and integrating its nuclear 
material with that of the host cell.  The late stage describes the process of viral mRNA 
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and protein production, viral assembly and emergence of mature virions from the host 
cell.  
The Early Phase 
The HIV-1 envelope is a lipid bilayer derived from the host cell and containing 
projections formed from glycoproteins known as gp120 and gp41 encoded on the env 
gene (Muesing, Smith et al. 1985).  HIV-1 infects mainly CD4+ T cells and macrophages 
by gp120 interaction with the cell surface receptor CD4 (Dalgleish, Beverley et al. 1984) 
and a chemokine co-receptors, like CCR5 (Wells, El Proudfoot et al. 1996).  This leads to 
exposure of the gp41 fusion domain to the cell membrane and rearrangement of the viral 
envelope resulting in fusion of the viral and host cell membranes (Engelman and 
Cherepanov 2012) releasing the viral core to the interior of the host cell.   
The core contains two copies of single stranded viral RNA tightly bound to gag 
encoded p7 nucleocapsid protein, and proteins necessary for viral replication, such as 
reverse transcriptase and integrase, surrounded by the mature capsid formed from gag 
encoded p24 (Fukui, Imura et al. 1993).  Uncoating of the core disassembles the capsid 
shell (Ambrose and Aiken 2014) and likely triggers reverse transcription of viral RNA 
(Fitzon, Leschonsky et al. 2000).   
The RNA is reverse transcribed into double stranded DNA by two pol gene 
products, p66 and p51, that form a heterodimer yielding the reverse transcriptase enzyme 
(Veronese, Copeland et al. 1986) capable of RNA to DNA polymerase, DNA to DNA 
polymerase and ribonuclease H functions.  The double stranded DNA along with several 
viral proteins including integrase and Vpr form a pre-integration complex (PIC) 
(Bukrinsky, Sharova et al. 1993) and are transported to the nucleus in a manner that has 
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not yet been fully elucidated (De Rijck, Vandekerckhove et al. 2007).  Once nuclear 
localization occurs a third product of the pol gene, integrase, cuts the host chromosomal 
DNA and joins the 3’end of the viral DNA to the cellular DNA (Bushman, Fujiwara et al. 
1990).  Host enzymes then complete the process joining the 5’ ends of the viral DNA to 
the host DNA to establish a stable provirus.   
The Late Phase 
 Transcription of the integrated provirus now proceeds to produce viral mRNA 
utilizing the host cellular machinery.  The viral trans-activator of transcription (Tat) 
protein recruits the host factors P-TEFb, CDK9, and cyclin T1 to the viral transactivation 
response (TAR) element found at the 5’ end of initiated viral transcripts to act as a 
promoter element (Fujinaga, Cujec et al. 1998), and stimulates CDK9-mediated 
phosphorylation of RNA polymerase II (Zhou, Halanski et al. 2000) greatly enhancing 
transcription elongation.  While small viral mRNAs are easily exported from the nucleus, 
larger mRNAs require help from the viral regulator of expression, Rev.  Multiple Rev 
molecules bind to the Rev response element (RRE) found in the env coding region of 
unspliced mRNA (Malim, Hauber et al. 1989) and the presence of a nuclear export signal 
(NES) facilitates egress of the Rev-bound unspliced mRNA from the nucleus (Fischer, 
Huber et al. 1995).   
 Translation of cytoplasmic, viral mRNA to protein necessary for virion assembly 
and budding also utilizes cellular machinery ie. the rough endoplasmic reticulum and 
cytosolic polysomes.  Virion morphogenesis begins when the necessary factors, mainly 
viral genomic RNA, the Env proteins, and the Gag polyprotein, are transported to the 
plasma membrane. The different Gag polyprotein domains work in concert to complete 
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assembly.  Multiple Gag polyproteins anchor by their MA domains collectively at 
specific regions of the plasma membrane.  The CA domains interact to create a spherical 
Gag lattice that organizes the virion and distorts the membrane.  The viral genomic RNA 
is secured on the NC domain while viral accessory proteins and factors in the ESCRT 
pathway are recruited and bound by the p6 region.  The cellular ESCRT pathway is 
responsible for plasma membrane remodeling and scission and has been hijacked to 
complete budding of the new virion from the host cell.  Maturation of the immature 
virion can occur concurrently or just after budding and relies on cleavage of the Gag 
polyproteins by the viral protease enzyme.  Rearrangement of the fully processed proteins 
leads to a mature infectious particle (Sundquist and Kraeusslich 2012).  These mature 
virions are now capable of infecting new cells. 
 While many HIV-1 infected CD4+ T cells will play host to viral replication before 
undergoing apoptosis early during the innate immune response, this is not a universal 
outcome.  Some infected cells enter a state known as latency.  This is a reversible 
condition that exists when an infected cell is capable of but does not actively produce 
virus particles (Eisele and Siliciano 2012).  This is not the principal means for HIV to 
evade the host immune response as it is in the Herpesviridae family of viruses (Perng and 
Jones 2009).  The primary means of immune escape by HIV is rapid evolution (Borrow, 
Lewicki et al. 1997; Richman, Wrin et al. 2003).  However with the success of HAART 
at diminishing active production of virus, the populations of latently infected cells known 
as reservoirs have taken on new importance and frustrated work towards a cure.   Because 
latent cells maintain the ability to produce functional virus (Pantaleo, Graziosi et al. 
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1993; Chun, Stuyver et al. 1997), lapses in HAART lead to reactivation of latent cells and 
a rebound in viremia (Davey, Bhat et al. 1999).   
Latent infections probably develop early after the initial host infection and can 
occur in both active and resting CD4+ T cells (Chavez, Calvanese et al. 2015).  Most of 
the active CD4+ cells that eventually make up the latent pool were probably infected 
while transitioning to a resting state from an active state and were not productive.  
However there is new evidence that a small number of cells actively produce virus and, 
through an unknown process, revert to a resting state (Chavez, Calvanese et al. 2015).  
The mechanisms for producing latently infected cells are still unclear but there is 
evidence that location and orientation of viral genome integration may play a role.  
Integration has been reported to occur ~90% of the time at sites within genes that are 
actively transcribed in resting CD4+ T cells (Han, Lassen et al. 2004).  The many open 
questions still surrounding HIV mean that it remains an important and interesting area of 
research. 
 
1.4 p53-MEDIATED RESPONSE TO HIV-1 INFECTION 
“The immune system has only limited success in opposing infection by HIV” (Audige, 
Urosevic et al. 2006) 
 The p53 response to HIV-1 infection is likely multifaceted and dependent on a 
number of factors such as cell type and phase of infection.  p53 has been implicated in 
mediating cell cycle arrest and apoptosis and also moderating transcription of the viral 
genome from the LTR through response to type 1 IFN, DNA damage and HIV encoded 
proteins. Again the pattern of PTM likely determines the subsequent actions of p53. 
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These actions may in part be hijacked and utilized by the virus for its own preferred 
outcome, be that viral replication, latency or apoptosis.   
 It is difficult to study the initial steps of HIV infection in humans, however 
attempts to illuminate this early stage using SIV infection in rhesus macaques offers 
some insight.  Plasmacytoid dendritic cells (pDCs) are the initial predominant cell type to 
arrive at the site of infection (Kwa, Kannanganat et al. 2011).  SIV/HIV then activates 
pDCs to produce chemokines and cytokines that attract other immune cells, such as 
CD4+ T-cells, leading to a robust and systemic infection (O'Brien, Manches et al. 2013). 
 While pDCs do not show a reduction in cell viability (Yonezawa, Morita et al. 
2003) and are poor sources for viral replication after HIV-1 infection, they are the 
principal producers of type 1 IFN (Ferbas, Toso et al. 1994).  Type 1 IFN is at least 
partially responsible for the upregulation of p53 mRNA and protein in HIV-1 infected 
CD4+ T cells (Imbeault, Ouellet et al. 2009; Imbeault, Lodge et al. 2009).   
 Another method of p53 activation following HIV-1 infection, involves the HIV-1 
glycoproteins, both the Env complex, made up of gp120 and gp41, and soluble gp120.  
Infected cells expressing the Env complex on their surface are able to fuse with 
uninfected cells containing CD4 receptors and CXCR4 or CCR5 co-receptors, creating 
syncytia, and inducing phosphorylation of p53 and upregulation of p53 targets, such as 
PUMA, leading to mitochondrial membrane permeabilization and apoptosis (Genini, 
Sheeter et al. 2001; Perfettini, Castedo et al. 2005).  This appears to be a major source of 
immune cell depletion in the progression of HIV-1/AIDS. 
 After p53 is activated it is capable of regulating transcription from promoter REs.  
Regulation of transcription in mammalian cells is one of the most important and well-
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studied functions of p53, but p53 also has the ability to regulate transcription from viral 
promoters.  The HIV-1 LTR has been shown to be yet another viral promoter that can be 
regulated by p53.  Numerous groups have reported that wild-type p53 has an inhibitory 
effect on transcription from the HIV-1 LTR (Duan, Ozaki et al. 1994) while some mutant 
forms of p53 have been shown to increase transcript elongation (Subler, Martin et al. 
1994).  The mechanisms by which p53 regulates HIV-1 LTR transcription elongation are 
still being identified.  Reports have been made of complex formation with TATA box 
binding protein (TBP) and Sp1 (Borellini and Glazer 1993; Chen, Farmer et al. 1993).  
More recently it was suggested that cdk9 was phosphorylating p53 along with Mdm2 
thereby stabilizing p53 and leading to its accumulation, which in turn decreased 
transcriptional elongation from the HIV-1 LTR (Bagashev, Fan et al. 2013).  Pirh2 was 
also reported to be phosphorylated by cdk9 which led to its inactivation (Bagashev, Fan 
et al. 2013).  This is particularly interesting in light of the fact that the inhibitory effects 
of p53 on the HIV-1 LTR reported were transitory and transcription elongation was 
salvaged possibly by the activity of Pirh2 (Mukerjee, Claudio et al. 2010).  It has also 
been noted that overexpression of p53 prevents phosphorylation of serine 2 in the 
carboxy terminal domain of RNA polymerase II which is necessary for efficient 
transcription elongation from the HIV-1 LTR (Mukerjee, Claudio et al. 2010). It is no 
surprise that the effect of p53 on HIV transcription has been and continues to be a topic 
of interest.    
In addition to its trans-activating role, p53 has been found to interact with a 
couple of HIV-1 factors.  For example HIV-1 Vpu has been reported to inhibit 
ubiquitination of p53 by β-TrcP promoting p53 stability and accumulation and ultimately 
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stimulating p53-mediated apoptosis in T cells (Verma, Ali et al. 2011).   There is also 
evidence of p53 interacting with the Tat protein, but the mechanisms and effects of this 
complex are still being investigated. 
 
1.5 p53 AND HIV-1 “TRANS-ACTIVATOR OF TRANSCRIPTION” 
 As was previously described, p53 is upregulated by several pathways perhaps cell 
type specifically after HIV-1 infection.  For certain cell types the actions of p53 might be 
hijacked by the virus and utilized in a manner detrimental to the host, such as wide-
spread apoptosis in T cells.  Our interest was in determining whether or not the actions of 
p53 could be mitigated by the HIV-1 factor Tat, prolonging the cellular life span to allow 
for completion of the viral life cycle.  This would be similar to the actions of the p53 
responsive factors found in the small tumor viruses; SV40 T antigen, HPV E6, etc. 
 Numerous viral factors including some produced by HIV have been shown to 
interact with p53 and other players in the p53 pathway.  One such factor is HIV-1 Tat.  
Most isolates of the HIV-1 virus produce Tat protein that consists of 101 amino acids.  
However a few isolates are known to produce a functional 86 amino acid version of the 
Tat protein.  Tat was discovered because of its role as a trans-activating protein, 
responsible for enhancing transcription from the HIV-1 LTR. Eukaryotic RNA 
polymerase II is capable of forming short HIV-1 transcripts but is inefficient at 
transcription elongation.  Tat binds both with the eukaryotic positive transcription 
elongation factor (P-TEFb), a complex of cyclin T1 and cyclin dependent kinase 9 
(Cdk9), and the TAR stem-loop structure of newly synthesized HIV-1 mRNA.  These 
associations lead to phosphorylation of RNA polymerase II by Cdk9 and initiate efficient 
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transcription of full length HIV-1 mRNAs.  Tat also recruits other cellular proteins 
necessary for relieving repression of the HIV-1 LTR, such as the CREB-binding protein 
(CBP)/ p300 complex (Romani, Engelbrecht et al. 2010).   
Tat has also been implicated in several other functions since its discovery,   
including regulation of gene expression from other viruses like polyomavirus BK 
(Gorrill, Feliciano et al. 2006) and from host cells leading to downstream effects 
including the inhibition of apoptosis (Zheng, Yang et al. 2007) and immune suppression 
(Gupta, Boppana et al. 2008).  Tat has also been linked to the increase in cancers seen in 
AIDS patients (Nunnari, Smith et al. 2008), and to the onset of HIV-associated dementia 
caused by induction of neuronal apoptosis (Haughey and Mattson 2002).  Tat is fast 
getting a reputation as a versatile protein with a full dance card, however its association 
with p53 has yet to be fully elucidated. 
  p53 has been reported to inhibit Tat transactivation of the HIV-1 LTR (Duan, 
Ozaki et al. 1994; Li, Wang et al. 1995) however Tat has also been demonstrated to 
suppress transcription from the p53 promoter (Li, Wang et al. 1995).  These studies 
examining interaction between p53 and Tat have indicated binding does occur.  Therefore 
a detailed examination of the structural and biophysical characteristics of the interaction 
was performed using peptide mapping, fluorescence anisotropy, and NMR spectroscopy.  
It was determined that amino acids 1-35 and 47-57 of Tat bind directly to the 
tetramerization domain of p53 which corresponds to residues 326-355 (Gabizon, Mor et 
al. 2008).   
A few studies have attempted to determine the cellular ramifications of p53 and 
Tat binding.  One such study found that the presence of Tat resulted in the loss of the 
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G1/S checkpoint after DNA damage induced by gamma irradiation.  The G1/S checkpoint 
is regulated by the p53 target, p21, and the levels of p21 were found to be decreased 
when Tat was present.  Because their results also indicated that wild-type Tat was able to 
inhibit p53 transcription activation while mutant Tat was not, it was tentatively suggested 
that the decrease in p21 and the failure of the G1/S checkpoint was caused by inhibition 
of p53 transactivation (Clark, Santiago et al. 2000).  
The objective of the studies presented here was to identify whether the presence 
of HIV-1 Tat in vitro would inhibit the ability of p53 to trans-activate its downstream 
targets, p21 and bax.  This was carried out by introducing Tat into the U2-OS cell line 
either by transient or stable transfections and activating p53 with the DNA damaging 
agents Camptothecin, Cisplatin, Doxorubicin, and Etoposide.  The effects on p21 and bax 
promoter activity, mRNA, and protein were studied using luciferase assays, qPCR, and 
immunoblotting, respectively. Because of the complex nature of HIV infection and its 
tendency towards latent infection which cannot at this point be eradicated even with 
HAART, elucidating the interactions between p53 and HIV factors like Tat is an 
important goal.   
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CHAPTER 2 
MATERIALS AND METHODS 
2.1 PREPARATION OF TAT HA EXPRESSION VECTOR AND CREATION OF TAT 
POSITIVE CELL LINES 
In order to study the p53 response in the presence of the HIV-1 Tat protein, the 
pcDNA3 Tat HA expression vector (Addgene plasmid 14654) and the human 
osteosarcoma U2-OS cell line was used.  The pcDNA3 Tat HA plasmid encodes a wild-
type, 101 amino acid version of the HIV-1 Tat protein tagged with influenza 
hemagglutinin (HA).  This vector also contains a selectable marker for neomycin 
resistance. The U2-OS cell line was chosen because it produces wild-type p53 and can be 
used to study the p53 DNA damage response pathway which includes upregulation of 
p21 and bax.  The human osteosarcoma cell line U2-OS was grown in Dulbecco’s 
Modified Eagle’s medium (DMEM) containing 10% fetal bovine serum, 4.5 g/L glucose, 
100 U/ml penicillin, 100 ug/ul streptomycin, and 2 nM L-glutamine.     
U2-OS cells were grown to confluency and split 1.45 x 106 in 100 mm cell culture 
dishes.  After 24 hours the cells were transfected with 2.5 ug and 5 ug of pcDNA3 Tat 
HA expression vector using TransFast Transfection Reagent (Promega) in a 1:1 charge 
ratio of TransFast reagent to DNA.  Selection of cells positive for the pcDNA3 Tat HA
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plasmid was achieved by addition of 200 ug/mL Geneticin G418 sulfate (GIBCO) to the 
growth medium. Clones were expanded, then PCR was used to test for the presence of 
the pcDNA3 Tat HA vector and immunoblotting with the HA probe (Santa Cruz 
Biotechnology) was used to test for the production of Tat HA protein. The U2-OS Tat 
HA cell lines were grown in DMEM with identical supplementation as the U2-OS cell 
line plus 200 ug/ml G418.   
The pcDNA3 Tat HA expression vector, and the pTRE2 vector (Clontech), that 
contains the Tet-responsive promoter PhCMV*-1, were digested with the restriction 
enzymes Not I and BamH I.  The Tat HA fragment was gel purified and ligated to the 
pTRE2 plasmid and will herein be referred to as the “pTRE2 Tat HA” Tet-induced 
expression vector (Figure 2.1).   
 
 
  
 
 
The U2-OS Tet-On Cell Line (Clontech) expresses a tetracycline-regulated 
transactivator, rtTA, that in the presence of doxycycline binds to the Tet-responsive 
element (TRE) of the PhCMV*-1 promoter.  U2-OS Tet-On cells were grown to confluency 
and split 1.45 x 106 cells in 100 mm cell culture dishes.  After 24 hours the cells were co-
transfected with pTRE2 Tat HA vector and pSV2gpt vector using TransFast Transfection 
Reagent (Promega) in a 1:1 charge ratio of TransFast reagent to DNA.  Cells positive for 
the pSV2gpt plasmid were selected by addition of the GPT selection mixture (section 
2.2). Clones were expanded into 24 well plates and tested for the presence of Tat DNA 
Figure 2.1 Segment of pTRE2 Tat 
HA vector.      
  PhCMV*-1      Tat  HA 
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with PCR.  Cell lines positive for Tat DNA were then tested for protein production with 
immunoblotting using an HA probe (Santa Cruz Biotechnology). The U2-OS Tet-On 
cell line was grown in DMEM with identical supplementation as the U2-OS cell line plus 
200 ug/ml G418.   The U2-OS Tet-On Tat cell line was grown in DMEM with identical 
supplementation as the U2-OS Tet-On cell line plus 15 ug/ml mycophenolic acid, 250 
ug/ml xanthine, 15 ug/ml hypoxanthine, 2 ug/ml aminopterin, 10 ug/ml thymidine (GPT 
selection mixture).  Four DNA damaging agents were used to induce a p53 response in all 
cell lines; 14 uM Camptothecin, 35 uM Cisplatin, 1 uM Doxorubicin, and 10 uM 
Etoposide (all Sigma). 
 
2.2 PROTEIN EXTRACTION AND IMMUNOBLOTTING 
 Approximately 1 x 106 cells were plated on 100 mm cell culture dishes and after 
24 hours were treated with DNA damaging agents.  At the indicated time points the cells 
were washed with 5 mL PBS, harvested by scraping in 1 mL of PBS, and pelleted by 
centrifugation for 2 minutes.  The supernatant was removed by aspiration and the pelleted 
cells were lysed using 50 uL of RIPA buffer (50 mM Tris pH 7.5, 150 mM NaCl, 1% 
Triton X-100, 0.1% SDS) with 10 uL/mL HALT Protease Inhibitor Cocktail that includes 
1 mM AEBSF, 800 nM Aprotinin, 50 uM Bestatin, 15 uM E64, 20 uM Leupeptin, 10 uM 
Pepstatin A (Thermo Scientific) added, then sonicated.  The protein concentration was 
determined using Bradford Protein Assay (Bio-Rad) with a UV-1700 PharmaSpec UV-
VIS spectrophotometer (Shimadzu) reading at a wavelength of 595 nm.  Protein lysates 
were stored at -70 oC. 
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 Thirty ug of protein were mixed in a 1:1 ratio with Laemmli Sample Buffer (Bio-
Rad) and denatured by boiling at 100 oC for 3 minutes.  Samples were separated by SDS-
PAGE using 12% SDS-polyacrylamide gels and 1X Tris-glycine running buffer (25 mM 
Tris, 192 mM glycine, 0.1% SDS) at 200 V for 1 hour.  Gels were rinsed in 1X TBST (10 
mM Tris pH 8, 150 nM NaCl, 0.05% Tween-20) before protein was transferred by 
electrophoresis to Amersham Hybond-ECL nitrocellulose membrane (GE Healthcare) in 
protein transfer buffer (25 mM Tris, 192 mM glycine, 20% methanol) at 100 V for 1 
hour.  Membranes were rinsed in 1X TBST and incubated in 2% powdered milk in TBST 
overnight to block non-specific binding of antibodies.   
 Membranes were rinsed three times with 1X TBST, then probed by incubating for 
1 hour with the recommended dilutions of the following mouse monoclonal antibodies: 
1:2000 p53-421 (Calbiochem) with 1:2000 p53-DO1 (Calbiochem), 1:50 p21 (Santa Cruz 
Biotechnology), and 1:200 HA-probe (Santa Cruz Biotechnology).  Membranes were 
washed once with 1X TBST for 15 minutes, then two more times for 5 minutes, before 
being incubated in anti-mouse IgG-peroxidase antibody (Sigma-Aldrich) diluted 
1:2000010 for 1 hour.  Membranes were again washed once for 15 minutes and three 
times for 5 minutes.  All washes and incubations were performed on a shaker at room 
temperature.  
 Membranes were incubated in room temperature ECL Prime Western Blotting 
Detection Reagents 1 and 2 (GE Healthcare) mixed in a 1:1 ratio for 5 minutes.  One of 
two imaging methods were utilized.  In the first method a sheet of Kodak BioMax Light 
Film was placed over a membrane wrapped in Saran Plastic wrap and exposed until the 
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linear range was obtained.  In the second method the membrane was imaged using the 
ImageQuant LAS 4000 system (GE Healthcare).   
  
2.3 LUCIFERASE ASSAY 
 Approximately 5 x 104 cells were plated in each well of a 24-well plate.  After 24 
hours the cells were cotransfected with 100 ng/uL of a vector containing the firefly 
luciferase gene under the control of one of three promoters, p53, p21, or bax, along with 
10 ng/uL of the pRL-CMV vector which contains the Renilla luciferase gene under the 
control of the CMV promoter.  Twenty four hours after transfection some cells were 
treated with DNA damaging agents. At the indicated time, zero to twenty four hours post, 
the cells were harvested with 100 uL of Passive Lysis Buffer (Promega) incubated for 15 
minutes at room temperature on the shaker.  The experiments were run in duplicate or 
triplicate.  The samples were analyzed using the Dual-Luciferase Reporter System 
(Promega).  The luciferase readings were measured once with the Zylux FB12 
luminometer.  The ratio of Luciferase to Renilla was determined and averaged for each 
set of duplicates or triplicates and normalized to a control. Standard deviations were also 
determined for the duplicates or triplicates and normalized to the same control.  If an 
experiment was replicated then the normalized means were averaged and standard 
deviations were calculated from the normalized means. 
 
2.4 RNA PURIFICATION AND RT-qPCR 
 Approximately 1 x 106 cells were plated on 100 mm cell culture dishes and after 
24 hours were treated with DNA damaging agents.  At the indicated time points the cells 
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were washed with 5 mL PBS, harvested by scraping in 1 mL of PBS, and pelleted by 
centrifugation for 2 minutes.  The supernatant was removed by aspiration and the RNA 
was extracted using the Total RNA Purification Kit (Norgen Biotek).  The RNA 
concentration was determined using the Nanodrop 2000c (Thermo Scientific).  cDNA 
was transcribed from 2 ug purified RNA using the random decamers and the Reverse 
Transcription System (Promega).     
 Amplification of the genes p53, p21, bax, and PUMA was achieved using primers 
specific for use with Real-Time qPCR (Table 2.1) and the 7300 Real-Time PCR System 
(Applied Biosystems) with a denaturation step at 95 oC for 10 minutes, followed by 40 
cycles of denaturation at 95 oC for 15 seconds, primer annealing at 60 oC for 20 seconds, 
and primer extension at 72 oC for 40 seconds, and lastly a final extension at 72 oC for 5 
minutes.  The reactions were run in triplicate and error bars indicate that samples were 
run in multiple independent experiments.  The housekeeping gene GAPDH was used as 
an internal control.  Experimental genes were normalized to the housekeeping gene and 
analyzed using the 2-∆∆Ct method.  
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Table 2.1 Forward and reverse primer sequences used for quantitative Real-Time PCR 
(Invitrogen). 
 
Gene Forward Reverse 
GAPDH 5’-ACATCGCTCAGACACCATG-3’ 5’-TGTAGTTGAGGTCAATGAAGGG-3’ 
p53 5’-GCCATCTACAAGCAGTCACAG-3’ 5’-TCATCCAAATACTCCACACGC-3’ 
p21 5’-TGTCACTGTCTTGTACCCTTG-3’ 5’-GGCGTTTGGAGTGGTAGAA-3’ 
bax 5’-GACATGTTTTCTGACGGCAAC-3’ 5’-AAGTCCAATGTCCAGCCC-3’ 
PUMA 5’-CGACCTCAACGCACAGTAC-3’ 5’-CCTAATTGGGCTCCATCTCG-3’ 
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CHAPTER 3 
RESULTS 
3.1 EVIDENCE OF BINDING BETWEEN P53 AND HIV-1 TAT 
 Due to the evidence in the literature indicating the possibility of an interaction 
between the tumor suppressor p53 and the HIV-1 Tat protein our lab decided to test for 
direct binding between the two purified proteins (Duan, Ozaki et al. 1994; Li, Wang et al. 
1995; Clark, Santiago et al. 2000; Gabizon, Mor et al. 2008).  We first purified p53 and 
HIV-1 Tat proteins by cloning cDNAs of Tat-101 and human wtp53 into the pET-52 
vector.  Ni-affinity chromatography was used to purify the His-tagged proteins from E. 
coli, followed by separation on SDS-polyacrylamide gel electrophoresis with Coomassie 
blue staining and immunoblotting with anti-p53 and anti-Tat antibodies (Figure 3.1).   
 
 
 
 
 
 
 
 
Figure 3.1 Purification of p53 and Tat 
proteins.  His-tagged proteins were 
purified from E. coli by Ni-affinity 
chromatography, and assayed on SDS-
PAGE either with Coomassie blue 
staining (lane 1) or immunoblotting with 
anti-p53 and anti-Tat antibodies (lane 2). 
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Once purified, Tat and p53 proteins demonstrated complex formation in vitro 
when co-immunoprecipitated with anti-p53 antibody and immunoblotted with anti-Tat 
antibody (Figure 3.2A).  p53-Tat complexes were also co-immunoprecipitated from cell 
lysates of U2-OS cells transfected with the pcDNA3 Tat expression vector (Figure 3.2B).  
In collaboration with Dr. Yeh at the BRITE Institute in Durham, NC, complexes were 
also detected by florescence polarization assay between p53 and Tat peptides that 
correspond to published interaction sites, 1-35 and 47-57, when increasing the 
concentration of p53 (Figure 3.2C).  Unlabeled Tat competes with FITC-Tat for binding 
with p53 (Figure 3.2D). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
D
A 
C
B
 
Figure 3.2 Binding of p53 and HIV-1 Tat proteins and peptides.  A) 
Increasing amounts of purified HIV-1 Tat proteins were incubated with a 
constant amount of purified p53 protein, followed by incubation with anti-p53 
antibody coupled to sephadex, then precipitated and analyzed by western blot 
using anti-Tat antibody.  B) Increasing amounts of pcDNA3 Tat expression 
vector were transfected into U2-OS cells.  Cell lysates were incubated with 
anti-p53 antibody coupled to sephadex, precipitated and analyzed by western 
blot using anti-Tat antibody.  C) Increasing amounts of p53 were incubated 
with 16nM FITC-Tat and analyzed by florescence polarization assay.  D)  
Increasing amounts of unlabeled Tat peptide added to 160nM p53 and 16nM 
FITC-Tat and analyzed by florescence polarization. 
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Considering the evidence that p53 and Tat are capable of binding, we were 
interested in determining whether this interaction might minimize the innate host p53 
response to HIV infection in a manner similar to the interaction between p53 and the p53 
inhibitors produced by the small tumor viruses, such as SV40.  We tested whether the 
binding of p53 by Tat has a direct and negative effect on the ability of p53 to respond to 
DNA damage.  Our model system used U2-OS cells, because they naturally express wild-
type p53, which were manipulated to also express HIV-1 Tat.  We used several DNA 
damaging agents to induce a p53 damage response in cells both expressing and not 
expressing HIV-1 Tat and studied the response of p53 through upregulation of its targets, 
p21 and bax.   
 
3.2 EXPRESSION OF HIV-1 TAT IN U2-OS CELLS  
We created three U2-OS cell lines containing wild-type p53 that would also 
express HIV-1 Tat.  To create a cell line in which transcription of Tat could be induced, 
we transfected a plasmid containing the HIV-1 Tat HA gene under the control of an 
inducible pTRE2 promoter into Tet-On U2-OS cells.  Individual clones were harvested 
and tested for the presence of the pTRE2 Tat HA expression vector using PCR (Figure 
3.3).  Positive clones were then used western blotting to test for the presence of the Tat 
HA protein before and after induction with 2 ug/ml doxycycline (Figure 3.4).  We also 
transfected a pcDNA3 plasmid containing the same HIV-1 Tat gene under the control of 
a constitutively expressing CMV promoter into U2-OS cells and tested for the presence 
of the expression vector using PCR and for the HA tagged Tat protein using western 
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blotting (data not shown).  Clones positive for Tat protein were expanded and used in 
immunoblotting, luciferase assays, and real-time PCR.   
 
 
                
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3 Presence of pTRE2 TatHA plasmid in 
transfected cells. Tet-On U2-OS cells were incubated 
with pTRE2 TatHA inducible expression vector, 
pSV2gpt selection vector, and Transfast transfection 
reagent.  Clones were harvested and PCR was 
performed using primers for pTRE2 and Tat101.  Cell 
lysates from untransfected cells (lane 1), pure plasmid 
(lane 2), clone 1 (lane 3), clone 3 (lane 4), and clone 9 
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3.3 CHARACTERIZATION OF THE EFFECTS OF DNA DAMAGING AGENTS ON 
P53, THE P53 TARGETS, P21 AND BAX, IN CELLS EXPRESSING HIV-1 TAT 
 
3.3.1 PROMOTER ACTIVITY (LUCIFERASE ASSAY) 
In order to determine whether Tat was capable of inhibiting the p53 response to 
DNA damage, we began by studying the promoter activity of the p53 targets, p21 and 
bax, in the presence of increasing amounts of Tat using luciferase assays.  Typically after 
exposure to DNA damage an increase in p21 and bax promoter activity is reported.  If Tat 
is able to mitigate the p53 response we would expect to see a decrease in activity from 
the p21 and bax promoters following DNA damage when Tat is present.   
U2-OS cells were co-transfected with vectors carrying the luciferase gene under 
the control of either the p21 or bax promoter along with either 0, 10, 25, 50, 100, or 250 
ng of pcDNA3 HIV-1 Tat.  A vector containing the Renilla-luciferase gene was also 
included and acted as a control for transfection efficiency.  Twenty four hours post 
Figure 3.4 Presence of HA tagged Tat protein in transfected cells after addition of 
doxycycline.  Clones were left untreated or exposed to 2 ug/mL doxycycline to induce 
expression of TatHA protein in positive cells. First lane contains lysate from 
untransfected U2-OS cells as a negative control. 
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transfection some of the cells were treated with DNA damaging agents to induce a p53 
response.  The DNA damaging agents used were 14 uM Camptothecin, 35 uM Cisplatin, 
1 uM Doxorubicin, and 10 uM Etoposide.  Luciferase and Renilla activity were measured 
24 hours after the addition of DNA damaging agents to the cell culture media.  The 
normalized luciferase reading indicate the relative promoter activity under the observed 
conditions.   
The first set of experiments show a decrease in p21 promoter activity in the 
presence of Tat, as would be expected if Tat were able to inhibit p53 (Figure 3.5A).  The 
same was true of bax promoter activity when Doxorubicin was added, however not when 
Camptothecin or Cisplatin were present in the culture media (Figure 3.5B).  This 
decrease in activity was seen for both promoters even when no DNA damaging agent was 
used to induce p53, which might be explained by Tat decreasing even basal levels of 
activity.  However from these experiments we are unable to determine whether each of 
the DNA damaging agents can cause an increase in activity from the p21 or bax 
promoters in the absence of Tat.  While these results seem to support our hypothesis, 
A 
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there were some large standard deviations and small sample size, so we wanted to repeat 
the experiment and decided to focus on one DNA damaging agent, Doxorubicin. 
Next we repeated the luciferase assay three times with duplicate samples of each 
condition, using only one DNA damaging agent, Doxorubicin.  We also included 
transfections with two nonfunctioning Tat mutants that we did not expect to decrease p21 
or bax promoter activity.  The results fit our expectations in this regard since none of the 
data fit a trend in promoter activity decreasing as Tat concentration increases (Figure 
3.6).  However there was also no evidence of a decrease in p21 promoter activity in the 
presence of increasing amounts of full length Tat with p53 induction or without (Figure 
3.6A).  The trend of the data appears to show a decrease in the activity of the bax 
Figure 3.5 p21 and bax promoter activity after transfection with pcDNA3 TatHA and 
treatment with DNA damaging agents.  U2-OS cells were transfected with pcDNA3 
TatHA vector at 0, 25, 50, and 250 ng, and a luciferase vector controlled by either the 
p21 promoter (A) or the bax promoter (B).  Twenty four hours later cells were either 
left untreated or treated with 14 uM Camptothecin, 35 uM Cisplatin, or 1 uM 
Doxorubicin.  Error bars represent normalized standard deviations between duplicate 
samples. 
B 
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promoter with increasing concentrations of Tat, however the large standard deviations 
cannot allow us to conclude that these data support our hypothesis. 
A 
B 
Figure 3.6 p21 and bax promoter activity after transfection with full-length TatHA, or 
Tat mutants and treatment with 1 uM Doxycyline.  U2-OS cells were transfected with 
pcDNA3 TatHA or a mutant Tat vector at 0, 25, 50, or 250 ng, and a luciferase vector 
controlled by either the p21 promoter (A) or the bax promoter (B).  Twenty four hours 
later cells were either left untreated or treated with 1 uM Doxorubicin.  Error bars 
represent standard deviations between three sets of normalized averages.   
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 Because we could not be sure of the actual concentration of Tat being produced in 
the transfected cells, we decided to repeat the experiment with the Tat producing cell 
lines U2-OS TatHA pool and U2-OS TatHA C4 (clone 4).   We again tested the activity 
of the p53, p21, and bax promoters in the presence of Tat and with p53 induction from 
DNA damaging agents.  U2-OS cells were used as a control.  If Tat were able to block 
the downstream effects of p53 we would expect a decrease in p21 and bax activity in the 
Tat producing cell lines.  Since the p53 promoter is not typically induced, we did not 
expect to see a difference in activity in the presence of Tat.   
While the U2-OS TatHA pool response was similar to U2-OS and did not show a 
decrease in promoter activity when compared to the Tat free cells, we found it interesting 
that the U2-OS TatHA C4 cell line that constitutively expresses Tat protein, displayed 
higher baseline levels (without p53 protein induction through DNA damage) of activity 
from all three promoters; twice as high from the bax promoter (Figure 3.7C) and nearly 
three times higher activity from the p21 (Figure 3.7B) and p53 (Figure 3.7A) promoters.  
A 
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Figure 3.7 p53, p21, and bax promoter activity in U2-OS cells constitutively 
expressing HA tagged Tat and treated with DNA damaging agents.  U2-OS cells and 
U2-OS cells constitutively expressing TatHA either from a pool or a cloned cell line 
where transfected with a luciferase vector controlled by a p53 promoter (A), a p21 
promoter (B), or a bax promoter (C) and treated with either 14 uM Camptothecin, 35 
uM Cisplatin, 1 uM Doxorubicin, and 10 uM Etoposide.  Error bars represent the 
normalized standard deviation of duplicate samples.   
C 
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There was also still an increase in activity from all three promoters after the addition of 
DNA damaging agents even in the cells expressing Tat protein.  Therefore we again 
cannot conclude that this data supports our hypothesis that Tat inhibits the p53 DNA 
damage response.   
As was previously discussed HIV-1 infection is complex and the factors involved 
change in response to numerous influences such as cell type and stage of infection.  Due 
to the complicated nature of HIV-1 infection, we decided to look at p21 promoter activity 
at intervals over a 24 hour time frame in U2-OS cells and U2-OS TatHA C4 cells both 
untreated and exposed to the DNA damaging agent Cisplatin.  Because the inhibition of 
p53 by Tat might logically be the most useful early during infection, in order to maximize 
the rate of infection and number of infected cells before being destroyed by apoptosis, we 
wanted to measure p21 promoter activity early following DNA damage.  Given our 
hypothesis the anticipated outcome was little change in the p21 promoter activity over 
time when no DNA damaging agent is added, an increase in promoter activity in the U2-
OS cell line upon addition of Cisplatin, and no change or a decrease in activity in the U2-
OS Tat C4 cell line upon addition of Cisplatin.   
The untreated U2-OS cells show an interesting increase in p21 promoter activity 
up to hour 8 and then a decrease to hour 24 (Figure 3.8).  When the U2-OS cells were 
treated with the DNA damaging agent Cisplatin at 35 uM the activity of the p21 promoter 
does not increase from the baseline of 1.0 until hour 14 when it is 2.3 and remains at this 
higher level of activity at hour 24.   The U2-OS cell line constitutively expressing Tat 
showed a 2 times greater baseline activity at 0 hours than did the U2-OS cell line. The 
untreated U2-OS TatHA C4 cell line also displayed some level of fluctuation during the 
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time course, most notably however was the drop in p21 promoter activity from 1.97 at 0 
hours to 0.73 at 24 hours, which will be discussed in more detail in the following 
paragraph.  While the U2-OS TatHA C4 cells that were treated with 35 uM Cisplatin did 
not exhibit this drop at the 24 hour time point, they also did not exhibit an increase in p21 
promoter activity at any point over the baseline level of p21 promoter activity found in 
the Tat positive cell line that would indicate a p53 response to DNA damage similar to 
that seen in the U2-OS cell line exposed to Cisplatin.  While these results do not support 
our hypothesis in the anticipated manner, they also do not suggest that Tat is a benign 
factor in U2-OS cells in the presence or absence of DNA damage.   
 
 
Figure 3.8 p21 promoter activity in U2-OS and TatHA Clone 4 cells, untreated and 
treated with Cisplatin over 24 hours.  U2-OS cells and TatHA C4 cells were 
transfected with a luciferase vector controlled by a p21 promoter and treated with 35 
uM Cisplatin.  Cells were harvested 0, 2, 4, 8, 14, and 24 hours prior to treatment 
with Cisplatin.  Error bars represent the normalized standard deviation of duplicate 
samples. 
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Moreover the drop in activity in the untreated Tat positive cell line at 24 hours 
was of particular interest because all of the control samples for the other experiments 
were harvested at time points that would be analogous to the 24 hour time point shown 
here.  Therefore if this drastic decrease in activity seen at 24 hours was present in the 
other experiments, including qPCR and immunoblotting, it is possible that our control 
samples are deceptively low and that is why the experimental samples appear high in 
comparison.  At the very least it illustrates a problem with collecting only one time point 
when utilizing a dynamic system.    
However prior to the final luciferase assay in which we learned the importance of 
multiple time points, we performed several experiments to observe the effects 
downstream of promoter activity.  We assayed mRNA levels and protein levels of p53 
and the p53 targets, p21, and bax using qPCR and immunoblotting.  
 
3.3.2 mRNA EXPRESSION (QUANTITATIVE REAL-TIME PCR) 
In order to compare the relative levels of mRNA in our experimental cell lines, 
the cells were either left untreated or treated with a DNA damaging agent and harvested 
after 24 hours.  qPCR was used to amplify the genes p53, p21, and bax.  Also due to a 
suspicion that we were losing expression of the Tat gene after several passages in the 
TatHA C4 clone we ran the experiment using cells that experienced a minimal number of 
passages, and cells that experienced double that number. The cells that underwent few 
passages are referred to as “early” while those that were grown in culture for a month 
before the experiment are referred to as “late”.  If there were a loss of Tat expression 
occurring in these cells we would expect to see no difference in the control U2-OS cell 
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line and the “late” TatHA C4 cell line.  A decrease in p21 and bax mRNA expression in 
the TatHA C4 cell lines after p53 induction via DNA damaging agents would support our 
hypothesis that Tat is able to mitigate p53 activation of these targets.   
There were some differences in mRNA expression in all of the cell lines (Figure 
3.9), but the data does not support our hypothesis since neither the “early” nor “late” cell 
lines exhibit a decrease in p21 and bax mRNA levels compared to the level in the U2-OS 
cells when induced by DNA damaging agents.  The basal p21 mRNA expression level in 
the TatHA C4 cell line were not higher than the basal U2-OS level in the way that the 
promoter activity was.  The bax and p53 basal mRNA levels were only slightly higher in 
the C4 cells compared to the basal level in the U2-OS cells, up 1.5 from 1.0.   
The differences also do not clearly demonstrate a loss of Tat expression since the 
expression seen in the “late” TatHA C4 cell line does deviate from the expression of p21 
and bax seen in the U2-OS cell line for except the p21 levels when treated with 
Doxorubicin and Etoposide(Figure 3.9B).  Interestingly the mRNA expression in the 
“late” cells also deviates from mRNA expression in the “early” cells for reasons that are 
not entirely clear.  It is possible that this is another artifact of only selecting one time 
point in a system that seems to naturally be quite volatile over time. 
This experiment was repeated in the TatHA pool cell line and the pTRE2 TatHA 
inducible cell line with similar results (data not shown). 
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3.3.3 PROTEIN EXPRESSION (IMMUNOBLOTTING) 
 We also examined p53 and p21 protein expression in the pTRE2 Tat HA 
inducible cell line, the Tat HA pool, the Tat HA C4 cell line, and the U2-OS cell line 24 
hours after activation of p53 with DNA damaging agents.  If our hypothesis was correct 
we expected to see a decrease in the p21 protein in the presence of Tat after activation of 
p53 with DNA damage.  Based on our hypothesis we did not expect to see a change in 
p53 protein expression.  Our initial blot using the inducible Tat HA cell line is not shown 
due to high background, but it appeared to show a slight decrease in p53.  However when 
the experiment was repeated, the data showed no change in p53 or p21 protein expression 
when Tat was induced by the addition of doxycycline and p53 was activated by DNA 
Figure 3.9 mRNA levels in U2-OS and TatHA Clone 4 cells before and 
after DNA damage.  U2-OS and TatHA C4 “early” (few passages) and 
“late” cells were treated with DNA damaging agents and assayed by 
qPCR for p53 (A), p21 (B), and bax (C) mRNA expression. 
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damaging agents (Figure 3.10).  Expression of p21 protein after DNA damage in the Tat 
HA pool was also assayed and compared to the U2-OS cell line (Figure 3.11).  In this 
case the results indicated that the levels of p21 protein were lower in the Tat positive cell 
line than in the U2-OS control cell line when p53 is activated by DNA damage.  While 
this appears that Tat may be inhibiting p21 expression it is rather far downstream from 
the p53 trans-activating step which we hypothesized to be targeted.  As discussed in the 
next section, overall we have not been able to clearly demonstrate an effect of Tat on p53 
activity in this model system.  There are numerous possibilities for these results aside 
from the possibility that there is no affect due to a Tat-p53 interaction.  Considering the 
important role p53 has been shown to play in many viral infections, we find it unlikely 
that a viral protein that binds to p53 during infection has no effect on its activity. 
 
   
 
Figure 3.10 p53 and p21 protein expression in pTRE2 Tat HA inducible cell line.  
p53 and p21 protein levels with and without induction of Tat HA expression by 
doxycycline, and activation of p53 with 35 uM Camptothecin, 14 uM Cisplatin, 1 uM 
Doxorubicin, and 10 uM Etoposide.  Showing non-specific band as loading control. 
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Figure 3.11 p21 protein expression in U2-OS cells and Tat HA pool.  p21 protein 
level with and without presence of Tat HA, and activation of p53 with 35 uM 
Camptothecin, 14 uM Cisplatin, 1 uM Doxorubicin, and 10 uM Etoposide.  Lanes 1, 
3, 5, 7, and 9 are U2-OS cell line.  Lanes 2, 4, 6, 8, 10 are Tat HA pool.  Showing 
non-specific band as loading control. 
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CHAPTER 4 
CONCLUSIONS 
 Our hypothesis that Tat could mitigate the ability of p53 to transactivate its 
downstream targets was based on our own preliminary data and published reports of 
evidence of binding between Tat and p53 (Clark, Santiago et al. 2000; Gabizon, Mor et 
al. 2008).  There are also reports that Tat is able to regulate transcription of p53 while 
p53 can mitigate the trans-activating function of Tat (Duan, Ozaki et al. 1994; Li, Wang 
et al. 1995).  Our hypothesis took into account that the small tumor viruses produce 
factors capable of binding and inhibiting p53 as a way of escaping cell cycle arrest and 
apoptosis in order to complete the viral life cycle.   
Taken in concert our data do not indicate that the presence of Tat can inhibit the 
ability of p53 to induce the targets p21 and bax when p53 is induced by the DNA 
damaging agents 14 uM Camptothecin, 35 uM Cisplatin, 1 uM Doxorubicin, and 10 uM 
Etoposide in U2-OS cells.  The results of our luciferase assays, immunoblots, and qPCR 
do not convincingly and repeatedly show a decrease in the promoter activity, mRNA, or 
protein of p21 or bax in the presence of Tat when treated with DNA damaging agents.   
However we have evidence of a phenomenon in which the activity of the p21 
promoter decreases drastically in the presence of Tat at 24 hours.  We have also 
demonstrated that in U2-OS cells constitutively expressing Tat, the p53, p21, and bax 
promoters are all at least twice as active as in U2-OS cells not expressing Tat.  While 
these results do not support our hypothesis directly they do provide an interesting area of 
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future research.  We plan to further investigate the activity of the p53, p21, and bax 
promoters in the presence of the DNA damaging agents in the U2-OS and the U2-OS Tat 
C4 cell lines over a 24 hour timespan.  Eventually we hope to expand that to examine the 
levels of mRNA and protein as well.   
We also recognize that the system utilized in this study is imperfect for examining 
conditions in HIV infected cells.  We are currently working on a method of inducing p53 
using type-1 interferon instead of chemotherapeutic agents which will induce p53 PTMs 
and a host cellular response more similar to a cell that has been infected with HIV-1.  The 
DNA damaging agents may be activating a p53 pathway that is unrelated to viral 
infection.  When utilizing IFN to activate p53, we can monitor a p53 target specific to 
this pathway, IRF9 (Munoz-Fontela, Macip et al. 2008).  Also instead of using 
osteosarcoma cells we think the most biologically relevant cell type for this study would 
be a T-cell line expressing wild-type p53 or primary T-cells. Our collaboration with the 
Gatignol HIV lab at McGill University in which infections with HIV are being performed 
will hopefully allow us to carry out analogous experiments in T-cell lines that have been 
infected with HIV-1.  Although we have been unable to detect a consistent effect of Tat 
on p53 activity, there were still noteworthy differences in the Tat positive cells that make 
us eager to move forward in this area of research, exploring the interaction between the 
tumor suppressor, p53 and HIV-1 trans-activator of transcription, Tat. 
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